NBM-HD-1: A Novel Histone Deacetylase Inhibitor with Anticancer Activity
نویسندگان
چکیده
منابع مشابه
NBM-HD-1: A Novel Histone Deacetylase Inhibitor with Anticancer Activity
HDAC inhibitors (HDACis) have been developed as promising anticancer agents in recent years. In this study, we synthesized and characterized a novel HDACi, termed NBM-HD-1. This agent was derived from the semisynthesis of propolin G, isolated from Taiwanese green propolis (TGP), and was shown to be a potent suppressor of tumor cell growth in human breast cancer cells (MCF-7 and MDA-MB-231) and ...
متن کاملAnticancer activity of MS-275, a novel histone deacetylase inhibitor, against human endometrial cancer cells.
BACKGROUND Histone deacetylase inhibitors (HDACIs) can inhibit cell proliferation, induce cell cycle arrest and stimulate apoptosis of cancer cells. MATERIALS AND METHODS The effects of a novel HDACI, MS-275, on 4 endometrial cancer cell lines and normal human endometrial epithelial cells was investigated. Endometrial cancer cells were treated with various concentrations of MS-275 and its eff...
متن کاملHistone deacetylase inhibitors as novel anticancer therapeutics
Histone deacetylase inhibitors represent a promising new class of compounds for the treatment of cancer. Inhibitors of this kind currently under clinical evaluation mainly target the classical (Rpd3/Hda1) family of histone deacetylases. Of particular note, the U.S. Food and Drug Administration recently approved the first histone deacetylase inhibitor (Zolinza: Merck and Co., Whitehouse Station,...
متن کاملA Novel Suberoylanilide Hydroxamic Acid Histone Deacetylase Inhibitor Derivative, N25, with Improved Antitumor Activity
A mass of research have demonstrated that epigenetic gene modulation has been postulated to be an essential mechanism in cancer development and metastasis (Nelson et al., 2012). The modification of histone acetylation plays a critical role in epigenetics as the hotspot of international research (Sriraksa et al., 2013). Especially in histone tails the reversible acetylation of lysine residues ha...
متن کاملNVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma.
Histone deacetylase (HDAC) inhibitors are emerging as a promising new treatment strategy in hematologic malignancies. Here we show that NVP-LAQ824, a novel hydroxamic acid derivative, induces apoptosis at physiologically achievable concentrations (median inhibitory concentration [IC50] of 100 nM at 24 hours) in multiple myeloma (MM) cell lines resistant to conventional therapies. MM.1S myeloma ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Evidence-Based Complementary and Alternative Medicine
سال: 2012
ISSN: 1741-427X,1741-4288
DOI: 10.1155/2012/781417